10-K: Abpro Holdings Faces Delisting, Seeks Nasdaq Reinstatement

Abpro Holdings, Inc. reports continued operational challenges, including a Nasdaq delisting, while pursuing strategic financing and product development.

Summary

• Abpro Holdings, Inc. (New Abpro) filed its annual report for the fiscal year ended December 31, 2025, detailing significant operational and financial challenges.
• The company was delisted from the Nasdaq Capital Market effective February 23, 2026, due to non-compliance with listing rules, and its securities now trade on the OTC Pink Limited Market.
• Abpro is actively appealing the delisting decision and is focused on advancing its lead product candidates, ABP-102 (oncology) and ABP-201 (ophthalmology), through clinical development.
• The company has identified material weaknesses in its internal controls over financial reporting, though it has remediated one weakness related to wire transfer authorization.
• Abpro continues to seek additional capital through various financing arrangements, including equity and debt, to fund its ongoing operations and development programs.
• The company's financial statements indicate substantial doubt about its ability to continue as a going concern, with a need for significant additional funding.
• Despite the challenges, Abpro has made progress in its clinical development plans, with the IND application for ABP-102 cleared by the FDA in January 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the Nasdaq delisting, going concern uncertainties, material weaknesses in internal controls, and significant operating losses, despite some positive developments in clinical trial progress.

Positives

• The Investigational New Drug (IND) application for ABP-102/CT-P72 was cleared by the U.S. Food and Drug Administration (FDA) in January 2026, enabling the initiation of a Phase 1 clinical trial.
• The company has a clear strategy to advance its lead product candidates, ABP-102 and ABP-201, into clinical trials.
• Abpro has proprietary antibody discovery and engineering platforms (DiversImmune and MultiMabTM) that it believes provide competitive advantages.
• The company has entered into strategic collaborations with Celltrion, Inc. for ABP-102 and Abpro Bio International, Inc. for ABP-201, which provide potential for milestone payments and commercialization.

Negatives

• Abpro Holdings was delisted from the Nasdaq Capital Market effective February 23, 2026, and its securities now trade on the OTC Pink Limited Market, impacting liquidity and access to capital.
• The company has identified material weaknesses in its internal controls over financial reporting, which could affect its ability to ensure timely and reliable financial reports.
• There is substantial doubt about the company's ability to continue as a going concern due to its ongoing operating losses and lack of sufficient funding.
• Abpro has incurred significant net losses, with a net loss of $2.9 million for the year ended December 31, 2025, and an accumulated deficit of $119.0 million.
• The company has a very small employee base, with only one full-time employee and two part-time employees as of March 30, 2026.
• The company is in breach of its license agreement with MedImmune/AstraZeneca for ABP-201, which could lead to termination of the agreement.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital, and failure to do so could force it to delay, limit, reduce, or terminate operations.
• Product candidates are in early stages of development and have never been tested in human subjects; they may fail in development or suffer delays.
• The market may not be receptive to the company's product candidates based on its novel therapeutic modality.
• The company will need substantial additional funds to advance development of its product candidates and cannot guarantee sufficient funds will be available.
• The company's common stock is traded on the OTC Pink Limited Market, characterized by high volatility, low liquidity, and limited regulatory oversight.
• The company has identified material weaknesses in its internal controls over financial reporting, which could affect its ability to ensure timely and reliable financial reports and weaken investor confidence.
• The company's management team has had difficulty in successfully or efficiently managing its transition to being a public company.
• The company is in breach of its license agreement with MedImmune/AstraZeneca, which could result in termination and loss of intellectual property rights.
• The company may be unable to obtain U.S. or foreign regulatory approval for its product candidates, which would result in substantial harm to its business.
• Healthcare legislative reform measures, such as the One Big Beautiful Bill Act (OBBBA), may have a material adverse effect on the company's business and results of operations.

Future Outlook

The company expects to continue incurring operating losses and requires substantial additional capital to fund its operations and advance its product candidates through clinical development. Its future viability is largely dependent on its ability to raise additional capital through equity and debt financings, collaboration agreements, and research grants.

Management Comments

• Management has concluded that uncertainties around our ability to raise additional capital, combined with our cash on hand, raises substantial doubt about our ability to continue as a going concern.
• We will require additional financing to fund our future operations. Any failure to obtain additional capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.
• Our management team may not successfully or effectively manage our transition to a U.S.-listed public company that will be subject to significant regulatory oversight and reporting obligations under federal securities laws.

Industry Context

StockSavvy.ai notes that Abpro Holdings operates in the highly competitive and capital-intensive biotechnology sector, focusing on novel antibody therapeutics. The company's challenges with Nasdaq listing and its 'going concern' status are not uncommon for early-stage biotechs, but its progress with the ABP-102 IND clearance and strategic partnerships with established players like Celltrion are positive indicators.

Comparison to Industry Standards

• The company's net loss of $2.9 million for the year ended December 31, 2025, and accumulated deficit of $119.0 million are significant, but not unusual for pre-revenue biotechnology companies investing heavily in R&D.
• The delisting from Nasdaq and subsequent trading on the OTC Pink Market is a common occurrence for companies facing financial or compliance challenges, impacting liquidity and investor perception.
• The company's reliance on external financing, including equity and debt, is standard practice in the biotech industry to fund lengthy and expensive drug development cycles.
• The identification of material weaknesses in internal controls is a concern, but the company's stated remediation efforts are a necessary step towards improving financial reporting reliability.

Management Changes

Legal Proceedings

• A former director filed a lawsuit for approximately $748,000 in consulting fees, bonuses, and unpaid promissory note principal and interest; settled for approximately $390,000.
• A CRO vendor filed a lawsuit for approximately $640,000 plus additional damages for deceptive business practices; a judgment was entered for approximately $700,000.
• MSK demanded payments totaling approximately $1.2 million related to a license agreement termination.
• Demand for payment from Integral Molecular, Inc. in the amount of approximately $182, currently under negotiation.
• Demand for payment from Brookline Capital Markets in the amount of $140, currently under negotiation.

Related Party Transactions

• Promissory note agreement with ABI (a significant investor) for up to $6,000, with $4,225 converted into shares and the remainder repaid.
• Promissory notes issued to an executive and a director for deferred bonuses.
• Company entered into a consulting agreement with its CEO, Miles Suk, through BioCelsus International Inc., with compensation including base fee and RSUs.
• Loan agreement with CEO for $147 to fund directors and officers liability insurance premium.

Stakeholder Impact

• Shareholders face increased volatility and reduced liquidity due to trading on the OTC Pink Market and potential for further price declines.
• Investors may experience dilution from future equity issuances to fund operations.
• Creditors and business partners may face concerns regarding the company's going concern status and ability to meet financial obligations.
• Employees may be impacted by the company's financial instability and potential need for further workforce reductions.

Next Steps

• Continue to advance lead product candidates, ABP-102 and ABP-201, into clinical trials.
• Seek additional capital through equity and debt financings, collaboration agreements, and research grants.
• Pursue appeal of the Nasdaq delisting determination.
• Implement and test internal controls to address remaining material weaknesses.
• Hire additional research and development personnel as funding becomes available.

Key Dates

Recommendation

The company's delisting from Nasdaq, substantial doubt about its going concern status, material weaknesses in internal controls, and significant operating losses present a high-risk investment profile. While there are positive developments in product candidate progression, the immediate financial and operational challenges outweigh these potential future benefits, suggesting a sell recommendation for seasoned investors.

Keywords

Abpro Holdings, Form 10-K, Annual Report, Biotechnology, Antibody Therapeutics, Immuno-oncology, Ophthalmology, ABP-102, ABP-201, Clinical Trials, FDA Approval, Nasdaq Delisting, OTC Pink Market, Going Concern, Capital Raise, Internal Controls